Chelsea Drennan, PharmD(c) explains why hospital length-of-stay might be shorter in patients who are on a fluoroquinolone versus a beta-lactam.
Chelsea Drennan, PharmD(c) from the University of South Carolina School of Pharmacy explains why hospital length-of-stay might be shorter in patients who are on a fluoroquinolone versus a beta-lactam.
Interview transcript (slightly modified for readability):
For hospital length-of-stay, we found a statistically significant difference in the fluoroquinolone group. They stayed a day shorter than the beta-lactam group. We presume this difference is potentially because of an easier transition from intravenous (IV) to oral therapy with the fluoroquinolone versus having them on [say] a cephalosporin IV and then trying to switch them over to an oral therapy. With a fluoroquinolone, you can from IV levofloxacin or IV ciprofloxacin to oral therapy and it’s 1:1 dosing. So, it’s a pretty good option, and they do have pretty good oral bioavailability.
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.